Amendments to the Claims:

Please amend the claims as follows, without prejudice:

In the Claims:

1-45 (Canceled).

46. (Currently Amended) A serum-stable amphoteric liposomal formulation comprising a liposome with an aqueous interior and at least one active substance in the aqueous interior, wherein the liposomes comprise 10-60 mole-% neutral lipids, 30-50 mole-% cholesterol, and, as charged lipids, either 5-30 mole-% amphoteric lipids or a maximum of 50 mole-% of a mixture of cationic and anionic lipids,

~~neutral lipids with a membrane proportion of 10 to 60 mole-%,~~

~~cholesterol with a proportion of 30 to 50 mole-%,~~

~~and, as charged lipids, either~~

~~amphoteric lipids with a proportion of 5 to 30 mole-%,~~

~~or~~

~~mixtures of cationic and anionic lipids with an overall proportion of 50 mole% at maximum,~~

and wherein the active substance comprises at least one oligonucleotide.

47. (Currently Amended) The liposomal formulation according to claim 46, wherein the liposomes comprise ~~proportion of cholesterol is~~ 35 to 45 mole-% cholesterol and ~~the proportion of~~ 5 to 20 mole-% amphoteric lipids ~~is 5 to 20 mole-%~~.

48. (Previously Presented) The liposomal formulation according to claim 46, wherein the oligonucleotides are constituted of 5-100 deoxyribonucleotides, ribonucleotides or chemically modified derivatives thereof.

49. (Currently Amended) The liposomal formulation according to claim 46, wherein the oligonucleotides are present as single strands, and/or double strands~~, or in complex folding~~.

50. (Previously Presented) The liposomal formulation according to claim 46, wherein the oligonucleotide is an antisense oligonucleotide.

51. (Withdrawn) The liposomal formulation according to claim 46, wherein the oligonucleotide is an aptamer.

52. (Withdrawn) The liposomal formulation according to claim 46, wherein the oligonucleotide is a spiegelmer.

53. (Currently Amended) The liposomal formulation according to claim 46, wherein the liposome has a molar composition (in mole-%) selected from the group consisting of:

DMPC/MoChol/DMPS/Chol 40:10:10:40,
DMPC/AC/Chol 50:10:40,
DMPC/HisChol/DPPS/Chol 35:10:15:40,
DMPC/IsohistsuccDG/Chol 50:10:40,
DMPC/MoChol/DGSucc/Chol 35:10:15:40,
DMPC/MoChol/DGSucc/Chol 40:10:10:40,
POPC/MoChol/DGSucc/Chol 35:10:15:40,
DMPC/HistSuccDG/Chol 50:10:40,
POPC/MoChol/DPPS/Chol 40:10:10:40,
DPPC/DOTAP/DGSucc/Chol 20:10:30:40,
DPPC/HistChol/Chol 50:10:40,
DPPC/HistSuccDG/Chol 40:20:40,
DPPC/MoChol/DGSucc/Chol 20:10:30:40,
POPC/HcChol/Chol 50:15:35,
DPPC/HcChol/Chol 50:15:35,

POPC/HistPS/Chol 50:15:35,
DPPC/HistPS/Chol 50:15:3 5,
POPC/AC/Chol 50:15:35,
DPPC/AC/Chol 50:15:35,
DPPC/HistChol/Chol 50:15:35,
POPC/HistChol/Chol 50:15:35,
DMPC/MoChol/DGSucc/Chol 20:10:30:40,
POPC/HistSuccDG/Chol 50:15:35,
DPPC/IsoHistSuccDG/Chol 50:15:35,
DPPC/HistSuccDG/Chol 50:15:35,
POPC/IsoHistSuccDG/Chol 50:15:35,
DMPC/MoChol/DGSucc/Chol 20:10:30:40,
POPC/MoChol/CHEMS/Chol 40:10:10:40,
DMPC/HistChol/Chol 50:10:40,
POPC/DOTAP/CHEMS/Chol 30:10:20:40,
DMPC/HisChol/DGSucc/Chol 40:10:10:40,
POPC/HisChol/CHEMS/Chol 40:10:10:40,
DMPC/MoChol/CHEMS/Chol 40:10:10:40 and
POPC/MoChol/DGSucc/Chol 30:20:10:40.

54. (Withdrawn) A method of treating a mammal with a drug comprising administering to the mammal the drug in the liposomal formulation of claim 46.

55. (Withdrawn) The method of claim 54 wherein the mammal is a human.

56. (Withdrawn) The method of claim 54 wherein the liposomal formulation is administered parenterally.

57. (Withdrawn) The method of claim 54, wherein the liposomal formulation includes one or more active substances.

58. (Currently Amended) The liposomal formulation according to claim 46, wherein the liposomes comprise ~~proportion of cholesterol is~~ 35 to 45 mole-% cholesterol and ~~the proportion~~ 15 to 45 mole-% of said mixtures of cationic and anionic lipids~~is 15 to 45 mole %~~.

59. (Currently Amended) The liposomal formulation according to claim ~~4649~~, wherein the oligonucleotide is a small interfering RNA.

60. (Withdrawn) The liposomal formulation according to claim 46, wherein the oligonucleotide is a decoy oligonucleotide.